How Sex Hormones and Iron Biomarkers Influence Colorectal Cancer Progression: New Insights Into Tumor Biology and EMT

Simple Explanation of the Study

Colorectal cancer affects the large intestine and is a major contributor to cancer death and illness globally. Scientists have long known that male and female biological differences impact cancer risk and outcomes, but the details have remained murky. Similarly, although iron is a nutrient essential for cell growth, how its mismanagement in the body relates to cancer's behavior is not fully mapped.

This study looked at 82 colorectal cancer patients and 31 healthy people. The researchers measured levels of:

• Sex hormones (testosterone, estradiol, progesterone, LH, FSH)
• Iron-related markers (serum iron, transferrin, ferritin, % transferrin saturation, ceruloplasmin, ceruloplasmin/transferrin ratio)
• EMT-related proteins in tissue samples (MEMO1, E-cadherin, fibronectin, vimentin, vinculin)

Participants were grouped by sex, and results were analyzed to see if differences appeared between males and females or between healthy and cancer patients.

Key Findings (Step-by-Step)

1. Sex Hormone Changes
   
   • Females with CRC had higher estradiol and progesterone than healthy females.
   • Males with CRC had lower progesterone than healthy males. No major changes were seen in testosterone after adjusting for age.
2. Iron Biomarker Changes
   
   • Both men and women with CRC had lower serum iron, transferrin, and % transferrin saturation than controls, suggesting a form of iron deficiency, even when not anemic.
   • Ceruloplasmin and the ceruloplasmin/transferrin ratio were elevated in CRC patients of both sexes.
   • Ferritin levels, a storage form of iron, were not significantly different, indicating that the iron deficiency found is more about iron distribution/use rather than overall storage.
3. Links to Tumor Features
   
   • Serum hormone and iron marker levels correlated with tumor size and stage.
   • In females, estradiol and FSH were linked with lymph node involvement, and CEA (a standard cancer marker) reflected tumor stage and presence of metastasis.
   • In males, FSH was negatively correlated with metastasis and CEA also marked advanced tumors.
4. Iron Markers and Tumor Biology
   
   • Lower iron and higher ceruloplasmin levels tracked with bigger, more advanced tumors in both sexes. Iron deficiency wasn’t just a result of anemia, as these links held even in patients without anemia.
5. EMT Markers and Their Meaning
   
   • EMT is a process where tumor cells lose their “stickiness” (adhesion) and become more mobile, helping cancer spread.
   • In tissue comparisons, CRC tumors showed higher E-cadherin and lower vinculin/vimentin than healthy tissue, a pattern related to invasiveness.
   • Progesterone in the blood was associated with more fibronectin in healthy tissue in women and less vimentin in men, both proteins involved in cell movement and structure. These links disappeared in tumor tissue, suggesting cancer disrupts normal hormone effects.
6. Complex Interactions
   
   • The study found evidence that altered iron metabolism and hormone levels don’t just happen because of cancer—they may actively contribute to its progression.
   • Changes in how iron is handled in the body (especially less iron available for transport) may help cancer cells evade certain types of cell death and fuel the metabolic shifts needed for aggressive behavior.

Technical and Holistic Summary

This study provides granular evidence that circulating sex hormones and iron-handling proteins are associated with the molecular features and clinical course of CRC in a sex-specific manner. Higher progesterone in healthy mucosa supports a protective role against EMT-driven invasiveness, especially in women, but this regulatory effect is lost in tumoral tissue. Iron-related biomarkers, especially reduced % transferrin saturation and elevated ceruloplasmin/transferrin ratio, reflect a functional iron deficiency prevalent in CRC, independent of anemia status. This iron imbalance parallels higher tumor stage and shifts in EMT marker expression, implying these metabolic changes may foster malignancy by promoting cell plasticity, immune evasion, and resistance to ferroptosis. The disrupted correlation between hormonal and iron markers in tumor tissue underlines a breakdown in normal endocrine and metabolic regulation with malignant transformation.

Collectively, these findings underscore the interplay between endocrine, metabolic, and cellular processes in CRC, offering potential biomarkers (such as ceruloplasmin/transferrin ratio or hormone profiles) to guide prognosis and stratification. They also point toward key molecular pathways—EMT regulation, iron metabolism, sex steroid signaling—that could be targeted in new therapies aimed at halting progression and metastasis in a sex-aware, personalized manner.